Predicting biotech clinical trials & a new Alzheimer’s drug controversy
This week on "The Readout LOUD" podcast: a new Alzheimer's drug controversy and prediction markets for clinical trials and FDA drug reviews. Listen now.
Read the full articleYou might also wanna read
Biogen defends anti-tau drug after stock slides on Alzheimer’s readout
Biogen leaders took to an investor call today to defend the phase 2 readout of the company’s anti-tau Alzheimer’s disease candidate, which d
Experimental drug takes a new aim at Alzheimer’s, with promising early results
For years, scientists have struggled to crack one of Alzheimer’s biggest mysteries. That may finally be changing.
Experimental drug takes a new aim at Alzheimer’s, with promising early results
For years, scientists have struggled to crack one of Alzheimer’s biggest mysteries. That may finally be changing.
Experimental drug takes a new aim at Alzheimer’s, with promising early results
For years, scientists have struggled to crack one of Alzheimer’s biggest mysteries. That may finally be changing.
Experimental drug takes a new aim at Alzheimer’s, with promising early results
For years, scientists have struggled to crack one of Alzheimer’s biggest mysteries. That may finally be changing.
The Amyloid Hypothesis for Alzheimer's disease and Aducanumab
Dr. Erik Musiek discusses the amyloid hypothesis and the challenges clinicians face in navigating discussions on the use of aducanumab for A
Comments
Sign in to join the conversation.
No comments yet. Be the first.